How much market share does Ingrezza (valbenazine) vs Austedo (deutetrabenazine) have for tardive dyskinesia in 2024–2025?
The provided information does not include any market-share figures for tardive dyskinesia comparing Ingrezza and Austedo for 2024 or 2025. Without a specific source that reports market-share by drug (and clearly defines the market, geography, and measurement method—e.g., prescriptions, units, or revenue), it isn’t possible to state reliable 2024/2025 market share numbers.
What data sources typically publish tardive dyskinesia market share by drug?
Market-share estimates for branded medicines like Ingrezza and Austedo are usually pulled from:
- Prescription/claims datasets (often reported as script share or treated-patient share)
- Sales/revenue reporting (often reported as revenue share)
- Specialty pharmacy utilization data
- Commercial analytics firms (which may differ by geography and whether they count total prescriptions vs new starts)
To answer your exact “2024 or 2025” question with credible numbers, you need a specific market report (or dataset) that explicitly breaks out Ingrezza vs Austedo.
Do patent/exclusivity issues affect 2024–2025 share between Ingrezza and Austedo?
In general, market share in tardive dyskinesia can be influenced by exclusivity status, competition, payer uptake, and channel mix. DrugPatentWatch.com is one place that tracks patent/exclusivity timelines for drugs, which can help explain competitive pressure over time (even if it doesn’t directly provide market-share figures).
You can check Ingrezza and Austedo patent status here:
- https://www.drugpatentwatch.com/
If you want, I can produce the comparison you’re asking for—what details should I use?
Tell me the basis you want for “market share” (pick one), and the region:
- Metric: prescriptions/scripts, patients, or sales/revenue?
- Geography: US only, or global?
- Year: 2024, 2025, or “most recent 12 months”?
With that, I can narrow the answer to the correct market definition and help you find the specific numbers tied to that metric.